5PSQ-114 Adalimumab in patients with immune-mediated diseases: evaluating the transition to the biosimilar and patient-reported outcome measures (PROM)
Year: 2025
Type: conference-paper
Study design: Observational Study
Abstract: Background and Importance The introduction of biosimilars in treatment of immuno-mediated diseases benefits both healthcare systems and patients. Nevertheless, patient concerns about switching may affect adherence and long-term outcomes. Aim and Objectives Assess how patients perceive the switch from reference to biosimilar or between biosimilars. Material and Methods Observational longitudinal study where patients switching from Humira or Hyrimoz to Yuflyma complete surveys before and after to assess parameters such as self-administration ability, pain level and their impact, satisfaction rate, patient-reported improvement after switch and the underlying reason for it. Pain, improvement and satisfaction were rated on a 0to5 scale. Results 55 patients were included(mean age46±12, 60%women). The pre-switch survey was answered by 55 patients;58.2% treated with Hyrimoz and 41.9% with Humira . The most common diagnoses were Crohn’s disease(34.0%), Hidradenitis suppurativa(14.5%) and rheumatoid arthritis(9.1%). While 80% were able to self-administer it, 10.8% of patients required assistance. Pain was reported by 58.2% of patients on reference. Only 25.5% rated it at level 0, 14.5% at 1, 20.0% at 2, 18.2% at 3, 16.4% at 4 and 5.5% at the highest level. Pain was a challenge to continuing the treatment, a source of anxiety for 11.0% and reason to need assistance for 5.5%. Satisfaction with reference was rated at level 3 or lower for 25.5%, 4 by 25.5% and 5 by 49.0%. After switching to Yuflma, 40 patients completed the survey, 97.5% could self-administer, and 2.5% needed assistance. Sixty percent noticed a change in pain perception, 65.0% reported no pain, 12.5% rated it at level 1, 20.0% at 2 and 2.5% at 3. None found it a challenge for treatment. As for the improvement, 52.1% rated at level 5, 22.5% at 4, 7.5% at 3, 12.5% at 2 and 5.0% at 1 or lower. This was due to being less painful and easier for 30.0% and anxiety feelings decreased for 20.0%. Satisfaction level was rated at level 5 for 80.0%, 7.5% rated it at 3 and 4 and 2.5% at 2 and 0. Conclusion and Relevance Switching to the biosimilar improved PROM, with most patients self-administering treatment, experiencing less pain, and greater satisfaction. However, not all patients participated in the follow-up, limiting comparisons between groups. References and/or Acknowledgements Conflict of Interest No conflict of interest
Institution: Hospital Universitari Germans Trias i Pujol
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4408376409